Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 4, 2013, Pages 629-636

  Maruyama, Hiroki ^a   Takata, Takuma ^b   Tsubata, Yutaka ^c   Tazawa, Ryushi ^d   Goto, Kiyoe ^d   Tohyama, Jun ^d   Narita, Ichiei ^a   Yoshioka, Hidekatsu ^e   Ishii, Satoshi ^e  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Nagaoka Chuo General Hospital   (Japan)

^c Niigata Prefectural Central Hospital   (Japan)

^d NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^e OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; BIOLOGICAL MARKER; GLOBOTRIAOSYLCERAMIDE; GLYCOLIPID;

ADULT; ARTICLE; CASE REPORT; DIAGNOSTIC TEST ACCURACY STUDY; DIALYSIS; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEMANGIOKERATOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPHEDEMA; LYSOSOME STORAGE DISEASE; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-GALACTOSIDASE; BIOLOGICAL MARKERS; ENZYME ACTIVATION; FABRY DISEASE; GENETIC TESTING; GLYCOLIPIDS; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MASS SCREENING; MIDDLE AGED; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; SPHINGOLIPIDS;

EID: 84876013615     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08780812     Document Type: Article

References (29)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276: 1163-1167, 1967
2. Utsumi K, Kase R, Takata T, Sakuraba H, Matsui N, Saito H, Nakumura T, Kawabe M, Iino Y, Katayama Y: Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol 4: 49-51, 2000
3. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ: Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 64: 801-807, 2003
4. Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, Aerts JM, Boeschoten EW: a-Galactosidase A deficiency in Dutch patients on dialysis: A critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 18: 1581-1584, 2003
5. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtländer T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Födinger M, Sunder-Plassmann G: Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15: 1323-1329, 2004
6. Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y: Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol 9: 228-232, 2005
7. Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K, Araki E, Itoh K, Matsushita K, Hara M, Kuwahara K, Nakano T, Yasumoto N, Nonoguchi H, Tomita K: Identification of Fabry's disease by the screening of a-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol 64: 281-287, 2005
8. Bekri S, Enica A, Ghafari T, Plaza G, Champenois I, Choukroun G, Unwin R, Jaeger P: Fabry disease in patients with end-stage renal failure: The potential benefits of screening. Nephron Clin Pract 101: c33-c38, 2005
9. Merta M, Reiterova J, Ledvinova J, Poupetová H, Dobrovolny R, Rysavá R, Maixnerová D, Bultas J, Motán J, Slivkova J, Sobotova D, Smrzova J, Tesar V: A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 22: 179-186, 2007
10. Fujii H, Kono K, Goto S, Onishi T, Kawai H, Hirata K, Hattori K, Nakamura K, Endo F, Fukagawa M: Prevalence and cardiovascular features of Japanese hemodialysis patients with Fabry disease. Am J Nephrol 30: 527-535, 2009
11. Gaspar P, Herrera J, Rodrigues D, Cerezo S, Delgado R, Andrade CF, Forascepi R, Macias J, del Pino MD, Prados MD, de Alegria PR, Torres G, Vidau P, Sá-Miranda MC: Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet 11: 19, 2010
12. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ: Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105: 2812-2817, 2008
13. Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H: Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 100: 257-261, 2010
14. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd BerghWeerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM: Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802: 741-748, 2010
15. van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, Breunig F, Wanner C, Aerts JM, Hollak CE: Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812: 70-76, 2011
16. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W: Fabry's disease: Enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 81: 157-171, 1973
17. Shimotori M, Maruyama H, Nakamura G, Suyama T, Sakamoto F, Itoh M, Miyabayashi S, Ohnishi T, Sakai N, Wataya-Kaneda M, Kubota M, Takahashi T, Mori T, Tamura K, Kageyama S, Shio N, Maeba T, Yahagi H, Tanaka M, Oka M, Sugiyama H, Sugawara T, Mori N, Tsukamoto H, Tamagaki K, Tanda S, Suzuki Y, Shinonaga C, Miyazaki J, Ishii S, Gejyo F: Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum Mutat 29: 331, 2008
18. The Japanese Association of Medical Sciences: Guidelines for Genetic Tests and Diagnoses in Medical Practice, 2011. Available at: http://jams.med.or.jp/. Accessed February 18, 2011
19. Domínguez RO, Michref A, Tanus E, Amartino H: [Restless legs syndrome in Fabry disease: Clinical feature associated to neuropathic pain is overlooked]. Rev Neurol 45: 474-478, 2007
20. Mucsi I, Molnar MZ, Ambrus C, Szeifert L, Kovacs AZ, Zoller R, Barótfi S, Remport A, Novak M: Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant 20: 571-577, 2005
21. Shabbeer J, Yasuda M, Benson SD, Desnick RJ: Fabry disease: Identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genomics 2: 297-309, 2006
22. Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M: The Mainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65: 299-307, 2004
23. Lee BH, Heo SH, Kim GH, Park JY, Kim WS, Kang DH, Choe KH, Kim WH, Yang SH, Yoo HW: Mutations of the GLA gene in Korean patientswith Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet 55: 512-517, 2010
24. Togawa T, Tsukimura T, Kodama T, Tanaka T, Kawashima I, Saito S, Ohno K, Fukushige T, Kanekura T, Satomura A, Kang DH, Lee BH, Yoo HW, Doi K, Noiri E, Sakuraba H: Fabry disease: Biochemical, pathological and structural studies of the a-galactosidase A with E66Q amino acid substitution. Mol Genet Metab 105: 615-620, 2012
25. Andrade J, Waters PJ, Singh RS, Levin A, Toh BC, Vallance HD, Sirrs S: Screening for Fabry disease in patients with chronic kidney disease: Limitations of plasma a-galactosidase assay as a screening test. Clin J Am Soc Nephrol 3: 139-145, 2008
26. Gal A, Hughes DA, Winchester B: Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. J Inherit Metab Dis 34: 509-514, 2011
27. Gal A: Molecular genetics of Fabry disease and genotype-phenotype correlation. In: Fabry Disease, edited by Elstein D, Altarescu G, Beck M, Dordrecht, The Netherlands, Springer Science + Business Media B.V., 2010, pp 3-19
28. Nishino T, Obata Y, Furusu A, Hirose M, Shinzato K, Hattori K, Nakamura K, Matsumoto T, Endo F, Kohno S: Identification of a novel mutation and prevalence study for Fabry disease in Japanese dialysis patients. Ren Fail 34: 566-570, 2012
29. Kikumoto Y, Sugiyama H, Morinaga H, Inoue T, Takiue K, Kitagawa M, Saito D, Takatori Y, Kinomura M, Kitamura S, Akagi S, Sada K, Nakao K, Maeshima Y, Kitayama H, Makino H: The frequency of Fabry diseasewith the E66Q variant in the a-galactosidase A gene in Japanese dialysis patients: A case report and a literature review. Clin Nephrol 78: 224-229, 2012